DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Silver Spring MD 20993

February 9, 2017

Yolanda Giraldo, M.D. M.P.H
Resident, General Preventive Medicine
John Hopkins School of Public Health

Sidney Wolf, MD
Founder and Senior Advisor
Public Citizen's Health Research Group

Charles Natanson, M.D.
Critical Care Physician

Sammy Almashat, M.D., M.P.H.
Reseacher
Public Citizen's Health Research Group

Michael Carome, MD
Director
Public Citizen's Health Research Group
1600 20th Street, NW
Washington, DC 20009

Ian Roberts, M.B, B.Ch, F.R.C.P, F.P.H
Coordinating Editor
Cochran Injuries Group
Co-Director
Clinical Trains Unit, London School of Hygiene & Tropical Medicine

Dear Petitioners:

Your petition to the Food and Drug Administration requesting that the FDA immediately require the removal from the market of HES IV solutions was received by the Division of Dockets Management on 02/08/2017. It was assigned docket number FDA-2017-P-0867 and it was filed on 02/9/2017. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Dynna Bigby
Supervisory Administrative Proceedings Specialist
Division of Dockets Management
FDA/Office of the Executive Secretariat (OES)